Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the…
$12.14+4.75%
报价 2026-11-09
市值
$720.9M
EV
$567.3M
PE (TTM)
9.1x
预期 PE (FY2026)
9.8x
52 周区间距高点 -17.7%
$8.10$14.75
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-09不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZVRAZevra Therapeutics, Inc. | $720.9M | +4.7% | +52.9% | 95% | 9.1x | 6.8x | 18.0x | |
| CRVSCorvus Pharmaceuticals, Inc. | $954.8M | +7.7% | +100.0% | 0% | – | – | – | |
| RIGLRigel Pharmaceuticals, Inc. | $785.5M | +6.1% | +4.3% | 91.4% | 2.7x | 9.1x | 11.1x | |
| OLMAOlema Pharmaceuticals, Inc. | $644M | +0.4% | – | 0% | – | – | – | |
| RGNXREGENXBIO Inc. | $532.7M | +5.9% | -18.0% | 54.2% | – | – | – | |
| PRTAProthena Corporation plc | $450.5M | +10.1% | – | 95.3% | – | – | – | |
| NAGENiagen Bioscience Inc | $180.4M | +10.1% | +11.8% | 63.9% | 17.4x | 15.1x | 39.4x | |
| AKBAAkebia Therapeutics, Inc. | $147.6M | +32.8% | -5.1% | 78.9% | – | – | 10.6x | |
| GOSSGossamer Bio, Inc. | $65M | +9.0% | -57.8% | 99.6% | – | – | – | |
| 同行中位数 | – | – | -0.4% | 71.4% | 10.0x | 12.1x | 11.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。